Veristat Advances Game-Changing Pain and Inflammation Therapy
Veristat continues to support Antibe Therapeutics, a biotech company with a drug platform of game-changing therapeutics in pain and...
Veristat Supports 12% of all FDA NME Approvals in 2018, a Record-Setting Year for FDA...
Veristat Celebrates Its Support of over 75 Global Regulatory Submissions Since Its Founding
Veristat Supports Antibe Therapeutics for Pain and Inflammation Study
Upon receiving approval from Health Canada, Antibe Therapeutics selected Veristat to immediately begin work on part one of a Phase 2B...
Veristat Partners with TRI For Risk-Based Monitoring Technology
Veristat Partners with TRI to Provide Centralized and Risk-Based Monitoring Technology to Their Biopharmaceutical Clients
Veristat Strengthens Clinical Operations Capabilities - Acquires Topstone Research
Expanding Its Clinical Operations and Biometrics Teams Dedicated to Emerging, Small and Mid-Sized Biopharma
Veristat Congratulates Alnylam on the FDA Approval of ONPATTRO™
Continues Collaboration to Provide Regulatory Submission Support for Additional Patisiran Submissions
SOUTHBOROUGH, MA – August 20, 2018...
Veristat Congratulates Agios on the FDA Approval of TIBSOVO®
The First Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation
SOUTHBOROUGH, MA –...